JP2024016201A5 - - Google Patents

Download PDF

Info

Publication number
JP2024016201A5
JP2024016201A5 JP2023190846A JP2023190846A JP2024016201A5 JP 2024016201 A5 JP2024016201 A5 JP 2024016201A5 JP 2023190846 A JP2023190846 A JP 2023190846A JP 2023190846 A JP2023190846 A JP 2023190846A JP 2024016201 A5 JP2024016201 A5 JP 2024016201A5
Authority
JP
Japan
Prior art keywords
seq
sequence represented
represented
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023190846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024016201A (ja
JP7650336B2 (ja
Filing date
Publication date
Priority claimed from JP2020522004A external-priority patent/JP7383607B2/ja
Application filed filed Critical
Publication of JP2024016201A publication Critical patent/JP2024016201A/ja
Publication of JP2024016201A5 publication Critical patent/JP2024016201A5/ja
Priority to JP2025038002A priority Critical patent/JP2025090718A/ja
Application granted granted Critical
Publication of JP7650336B2 publication Critical patent/JP7650336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023190846A 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 Active JP7650336B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025038002A JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762575275P 2017-10-20 2017-10-20
US62/575,275 2017-10-20
US201762580303P 2017-11-01 2017-11-01
US62/580,303 2017-11-01
US201862623371P 2018-01-29 2018-01-29
US62/623,371 2018-01-29
JP2020522004A JP7383607B2 (ja) 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
PCT/US2018/056789 WO2019079772A1 (en) 2017-10-20 2018-10-19 SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020522004A Division JP7383607B2 (ja) 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025038002A Division JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Publications (3)

Publication Number Publication Date
JP2024016201A JP2024016201A (ja) 2024-02-06
JP2024016201A5 true JP2024016201A5 (enExample) 2024-04-10
JP7650336B2 JP7650336B2 (ja) 2025-03-24

Family

ID=66174267

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020522004A Active JP7383607B2 (ja) 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2023190846A Active JP7650336B2 (ja) 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2025038002A Pending JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020522004A Active JP7383607B2 (ja) 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025038002A Pending JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Country Status (12)

Country Link
US (2) US11578118B2 (enExample)
EP (1) EP3697895A4 (enExample)
JP (3) JP7383607B2 (enExample)
KR (2) KR102723182B1 (enExample)
CN (2) CN111479916B (enExample)
AU (2) AU2018351072B9 (enExample)
BR (1) BR112020007823A2 (enExample)
CA (1) CA3079681A1 (enExample)
IL (1) IL274082B1 (enExample)
MX (1) MX2020004063A (enExample)
SG (1) SG11202003024WA (enExample)
WO (1) WO2019079772A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
EP3844290A4 (en) * 2018-09-13 2022-07-06 Ramot at Tel-Aviv University Ltd. GENETIC MODIFICATION OF B-LYMPHOCYTE RECEPTORS AND THEIR USES IN ANTIGEN-INDUCED ANTIBODY SECRETION
CN111995674B (zh) * 2020-09-03 2022-02-11 中国人民解放军军事科学院军事医学研究院 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用
WO2023192936A2 (en) * 2022-03-30 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to produce b cells that express selected antibodies and gene products
CA3256953A1 (en) * 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
WO2025096483A2 (en) * 2023-10-30 2025-05-08 Be Biopharma, Inc. Engineered cell preparations

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102257A1 (en) 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
US20020106729A1 (en) * 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
DE10113776B4 (de) * 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2006115800A2 (en) * 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗igf−1r抗体およびその使用
AU2010232414A1 (en) 2009-04-03 2011-10-13 Duke University Mouse models
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
WO2011047442A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
CA2786664C (en) * 2010-01-08 2020-03-10 Immusoft Corporation Vectors and methods for transducing b cells
TWI539963B (zh) 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
EP2825670A4 (en) 2012-03-16 2015-11-04 Univ Rochester METHODS FOR PREDICTING THE CLINICAL OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA
WO2013148256A2 (en) 2012-03-27 2013-10-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the generation of immunoglobulin sequences
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
ES2701749T3 (es) 2012-12-12 2019-02-25 Broad Inst Inc Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
ES2536353T3 (es) 2012-12-12 2015-05-22 The Broad Institute, Inc. Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10993420B2 (en) * 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
JP6625971B2 (ja) 2013-06-17 2019-12-25 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
WO2014204723A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
DK3011031T3 (da) 2013-06-17 2020-12-21 Broad Inst Inc Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
US9914759B2 (en) 2013-07-19 2018-03-13 Vib Vzw Targeted modified TNF family members
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
KR20160089530A (ko) * 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Hbv 및 바이러스 질병 및 질환을 위한 crispr­cas 시스템 및 조성물의 전달,용도 및 치료적 적용
WO2015089351A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015089427A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのcrispr−cas系及び組成物の送達、使用及び治療適用
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
IL289736B2 (en) 2013-12-12 2025-09-01 Massachusetts Inst Technology Administration, use and therapeutic applications of CRISPR–Cas gene editing systems and gene editing preparations
EP3102589A1 (en) 2014-02-04 2016-12-14 Biogen MA Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US9512204B2 (en) 2014-03-31 2016-12-06 Board Of Regents, The University Of Texas System Humanized pertussis antibodies and uses thereof
EP3230457B1 (en) * 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
US20190264186A1 (en) 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1

Similar Documents

Publication Publication Date Title
JP2024016201A5 (enExample)
JP2025036561A5 (enExample)
JP2022079549A5 (enExample)
JP2023085476A5 (enExample)
JP6173911B2 (ja) 抗体誘導体
ES2199941T3 (es) Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j.
JP2018108081A5 (enExample)
CN115043938B (zh) SARS-CoV-2及其突变株的抗体及应用
JP2023093753A5 (enExample)
JP5512824B2 (ja) B型肝炎ウイルス表面抗原に特異的に結合するヒト抗体
JP2018537966A5 (enExample)
CN115397852B (zh) 工程化抗il-2抗体
RU2015107891A (ru) Антитела к asgpr и их применения
JP2019502712A5 (enExample)
JP2021500028A5 (enExample)
JP2023058590A5 (enExample)
TW201538524A (zh) 特異性結合人il-17a的分離的單克隆抗體
JP2005519580A5 (enExample)
JP2023015301A5 (enExample)
WO1998057993A9 (en) Secretory immunoglobulin produced by single cells and methods for making and using same
CA2283540A1 (en) Anti-fas antibodies
JPWO2021241616A5 (enExample)
RU2004108115A (ru) Рекомбинантные антитела и композиции, а также способы их создания и использования
JPWO2021110561A5 (enExample)
JPWO2020086730A5 (enExample)